04.16.14 | By
For the last 20 years, the federal 340B has helped biopharmaceutical companies and hospitals partner to share treatments and medicines at a discounted price with those who could not otherwise afford them. The program has helped millions of uninsured and vulnerable patients gain access to the treatments necessary to lead fuller — healthier lives. Unfortunately, the 340B program lacks an effective oversight mechanism to ensure the discounted treatments are reaching their intended recipients. The lack of oversight has led to an explosion in growth in the program – but not necessarily to the benefit of patients.
A new report from the Alliance for Integrity and Reform of 340B found that two thirds of hospitals participating in the 340B program delivered less charity care than the average for all other hospitals.
Given the important role the 340B program plays in the lives of millions of patients, we asked this week’s Conversations question:
We look forward to finding out what our contributors have to say about this important issue, and encourage you to join the conversation yourself by sharing your thoughts in the comment section.